Assessment of anti-IFNβ autoantibody levels did not reveal differences between severe COVID-19 patients who were positive or negative for anti-IFNα2 IgG, either in plasma or TBS samples (S2A and S2B Fig). This evidence concerns the gene IFNA2 and COVID-19.